NEW YORK (GenomeWeb) – Exact Sciences today reported preliminary fourth quarter revenue of $14 million to $14.5 million, slightly below analyst estimates of $15.9 million. The company also said it expects full-year 2015 revenues of $39 million to $39.5 million.

Exact said it completed 38,000 Cologuard tests during Q4, and about 104,000 tests during the year — 2015 was the first full year of commercialization for the non-invasive colorectal cancer screening test.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

What happens to scientific papers when certain journals are no longer published? Some scientists are trying to make sure they don't disappear forever.

A study in Microbiome finds that heavy drinkers have an unhealthy mix of bacteria in their mouths.

Doctors and patients are still trying to figure out what role at-home genetic testing should play in healthcare, Newsweek says.

In Genome Research this week, mismatch repair deficiency in C. elegans, retracing transcriptions start site evolution in the human genome, and more.